One-month delay in MTX initiation on RA outcomes: 1-year ancillary analysis of the VACIMRA trial
Authors' conclusion
Deferring MTX for 1 month after PCV13 to enhance immunity did not worsen RA disease control, radiographic progression or treatment escalation after 1 year of follow-up.
Study context
- Population
- Patients with early RA in the VACIMRA trial enrolled at the Montpellier centre (mean age 58 ± 14 years, DAS28-ESR 4.88 ± 0.94)96 analysable at M0, 83 at M12
- Participants
- 100 patients
- Comparison
- MTX started 1 month after pneumococcal conjugate vaccine (PCV13) vs MTX started immediately
- Primary endpoint
- Proportion in remission (DAS28-ESR < 2.6) or LDA (DAS28-ESR ≤ 3.2)
- Follow-up
- 1 year
Methodological detailssingle-centre (Montpellier)
- Single-centre (Montpellier)
Primary result
As reported in the abstract
Remission (DAS28-ESR < 2.6) or LDA (DAS28-ESR ≤ 3.2) · 12 months
- Remission: 53.7% vs 46.3%, similar (abstract does not say which rate is which group)
- P = 0.51
- Low disease activity (LDA): 75.6% vs 61.0%, similar (abstract does not say which rate is which group)
- P = 0.15
Further findings
| Outcome | DELAY | Immediate | P value |
|---|---|---|---|
| DAS28-ESR · 6 months | 2.66 (SD 1.07) | 3.28 (SD 1.34) | P = 0.02 |
| DAS28-ESR · 12 months | 2.23 (SD 1.03) | 3.00 (SD 1.16) | P < 0.01 |
DAS28-ESR at 1 and 3 months
- DAS28-ESR similar at 1 and 3 months
mSHS progression · 6 and 12 months
- mSHS progression comparable at 6 and 12 months
Original publication
One-month delay in MTX initiation on RA outcomes: 1-year ancillary analysis of the VACIMRA trial. Rheumatology (Oxford). Published 22 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →